KRTL Holding Group Highlights Bolivian Innovation CaviGuard, Manufactured by SIGMA, as Global Model in Non-Invasive Dental Care
- KRTL Biotech
- 2 days ago
- 5 min read
CaviGuard is designed to address the global burden of untreated dental caries, particularly in underserved and rural communities. The system eliminates the need for drills or anesthesia, allowing for safe, comfortable, and rapid treatment using a protocol based on silver diamine fluoride (SDF) and fluoride varnish (FV). Developed over more than a decade, CaviGuard has been deployed in thousands of patients and validated through field trials and academic research.
"CaviGuard exemplifies the kind of scalable, community-centered innovation that aligns perfectly with KRTL's international strategy," said Cesar Herrera, CEO of KRTL Holding Group Inc. “Its expansion into new markets is a reflection of both its clinical value and its manufacturing quality through SIGMA.”
Unlike conventional dental procedures that require drills, anesthesia, and clinical infrastructure, CaviGuard represents a novel medical device solution tailored for portability, cost-effectiveness, and patient comfort. By eliminating invasive steps, it lowers barriers to care—particularly in resource-limited settings. According to the World Health Organization, untreated dental caries is the most common health condition globally, contributing to the 3.5 billion people affected by oral diseases. The global dental consumables market—which includes products like fluoride varnishes and non-invasive cavity treatments—was valued at approximately USD 36 billion in 2024, according to Grand View Research. As the licensed manufacturer, SIGMA ensures each CaviGuard unit is produced in accordance with international GMP standards, supporting quality, consistency, and alignment with global public health objectives.
The CaviGuard system leverages a unit-dose protocol for hygienic, controlled application and includes a Proprietary housing and delivery system to optimize comfort and efficiency. Designed for ease of use in low-infrastructure settings, the treatment is already in use in:
Community and rural clinics across Bolivia
Public health programs in partnership with UNIVALLE and the Bolivian Food Bank
Clinics in Brazil aligned with national prevention strategies
Select providers in the United States focused on low-income and pediatric populations
“Our mission has always been to reduce barriers to essential oral health services,” said Patricia Wilstermann, CEO of SIGMA. “By producing CaviGuard at scale, we’re enabling frontline health professionals to treat cavities without fear, pain, or costly infrastructure.”
CaviGuard has also launched training and certification programs for dental professionals and public health providers. This includes partnerships with universities and nonprofit groups to ensure appropriate deployment and adherence to international standards.
Why It Matters
Dental cavities remain the most common chronic disease globally, affecting billions of people, particularly in low-resource environments where access to safe, affordable treatment is limited. CaviGuard directly addresses this global health challenge with a system that eliminates the need for drills, anesthesia, or electricity. Clinical outcomes have shown cavity arrest rates of up to 96%, offering a non-invasive and highly effective alternative to traditional dental care. By reducing treatment anxiety—especially in children—and enabling mass deployment in schools, mobile units, and community clinics, the solution meets both public health and practical demands. With its cross-border adoption already underway, CaviGuard exemplifies how innovation born in South America can transform global standards in oral health delivery.
To learn more about the CaviGuard system, visit: www.caviguard.com
About KRTL Holding Group, Inc.
KRTL Holding Group, Inc. (OTC: KRTL) operates through its subsidiaries KRTL Biotech, Inc. and KRTL International Corp. The Company leverages strategic synergies across biotech, technology, and emerging markets to drive growth and deliver shareholder value.
About KRTL Biotech, Inc.
KRTL Biotech, Inc., a 51% majority-owned subsidiary of KRTL Holding Group Inc. (OTC: KRTL), recently completed a merger with Industria Químico-Farmacéutica SIGMA Corp. S.R.L., integrating SIGMA’s decades of pharmaceutical expertise and infrastructure into KRTL’s international life sciences platform. This merger combines KRTL’s research, compliance, and global market access with SIGMA’s advanced Bolivian manufacturing capabilities, aligning both companies to deliver world-class pharmaceutical and nutraceutical solutions.
About Industria Químico Farmacéutica SIGMA Corp SRL
SIGMA is a Bolivian pharmaceutical manufacturer with more than five decades of experience in formulation, quality manufacturing, and commercialization of essential and complementary health products, including pharmaceuticals and nutraceuticals.
For more information:
Forward-Looking Statements
This press release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking statements” within the meaning of applicable securities legislation. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. Words such as “anticipates,” “will,” “believes,” “plans,” “expects,” “intends,” “projects,” “estimates,” “future,” and “opportunity” and similar expressions are used to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments and acquisitions; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company. Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law.
Comments